RT @Dr_Nick_Bikes: We hosted @jonatcoque...
RT @jonatcoquet: @Dr_Nick_Bikes @oNKo_in...
Calling all post-doc level scientists wa...
RT @Dr_Nick_Bikes: A hairy subgroup of t...
RT @eperlste: Biotech VCs appear to be c...
RT @skinucph: Can you get a brand new la...
RT @S_Foroutan: So honoured to have cont...
RT @Dr_Nick_Bikes: Brilliant commuting t...
Keen to work at the intersection of cutt...
RT @paulbeavis4: Currently looking for a...
Are you an experienced Senior Animal Tec...
RT @hanim_halim: Thank you @richberry198...
Meet one of our highly skilled Scientist...
The talents of our oNKo staff go far bey...
We're on the look out for a skilled Scie...
RT @ImranHouse: Very excited to announce...
Welcome to the oNKo family, Dr Imran Hou...
Jai Rautela and Chacko Joseph @chaks86 w...
RT @dramarija: @Innovation2T 🛫 with J...
In the second of our Staff Profile Serie...
Tune in to hear about how oNKo is breaki...
RT @benchling: Just two days away! Join ...
RT @benchling: Join us next week for our...
RT @Dr_Nick_Bikes: Privileged to work wi...
Teaser: As a talented scientist @S_Forou...
On #IWD2022 we are excited to launch our...
Three days to go! An exciting opportunit...
RT @richberry1983: Come and help us deve...
We're on the lookout for a Principal Sci...
Senior Scientist Level II - in vivo tumo...
oNKo-innate named Australian Emerging Company of the Year 2021
The cancer–natural killer cell immunity cycle
Monash University and oNKo-innate Announce Research Partnership
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies
Immunotherapy biotech scores Gilead partnership
Interest builds in next-generation cancer immunotherapies
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Announcing research collaboration with Gilead and Kite
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Molecular insight into targeting the NK cell immune response to cancer
The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
IL-15 signaling in NK cell cancer immunotherapy
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
Targeting natural killer cells in cancer immunotherapy
CIS is a potent checkpoint in NK cell-mediated tumor immunity
A crucial role for the homeodomain transcription factor Hhex in lymphopoiesis
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo